Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8(+) T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection

Mauricio A. Martins, University of Miami
Damien C. Tully, Ragon Institute of MGH, MIT and Harvard
Michael A. Cruz, University of Miami
Karen A. Power, Ragon Institute of MGH, MIT and Harvard
Marlon G. Veloso de Santana, University of Miami
David J. Bean, Ragon Institute of MGH, MIT and Harvard
Colin B. Ogilvie, Ragon Institute of MGH, MIT and Harvard
Rujuta Gadgil, Ragon Institute of MGH, MIT and Harvard
Noemia Lima, Instituto Oswaldo Cruz-FIOCRUZ
Diogo M. Magnani, University of Miami

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Virology
Volume: Volume 89, Number 21
Publisher: American Society for Microbiology | 2015-11-01, Pages 10802-10820
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01440-15
Permanent URL: https://pid.emory.edu/ark:/25593/rpr2p

Final published version: http://dx.doi.org/10.1128/JVI.01440-15

Copyright information:
© 2015, American Society for Microbiology. All Rights Reserved.
Accessed October 5, 2023 2:51 AM EDT
Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8 T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection


Department of Pathology, University of Miami, Miami, Florida, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA; Laboratório de Biologia Molecular de Flavivirus, Instituto Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brazil; Section on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA; Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA; International AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn Army Terminal, Brooklyn, New York, USA; Wisconsin National Primate Research Center, University of Wisconsin—Madison, Madison, Wisconsin, USA; Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

ABSTRACT
Certain major histocompatibility complex class I (MHC-I) alleles (e.g., HLA-B*27) are enriched among human immunodeficiency virus type 1 (HIV-1)-infected individuals who suppress viremia without treatment (termed “elite controllers” [ECs]). Likewise, Mamu-B*08 expression also predisposes rhesus macaques to control simian immunodeficiency virus (SIV) replication. Given the similarities between Mamu-B*08 and HLA-B*27, SIV-infected Mamu-B*08 animals experience a delayed and atypical escape pattern. These features led us to postulate that a monotypic vaccine-induced Nef-specific CD8 T-cell response would facilitate the development of elite control in Mamu-B*08 animals following repeated intrarectal challenges with SIVmac239. To test this, we vaccinated Mamu-B*08 animals with nef inserts in which Nef RL10 was either left intact (group 1) or disrupted by mutations (group 2). Although monkeys in both groups mounted Nef-specific cellular responses, only those in group 1 developed Nef RL10-specific CD8 T cells. These vaccine-induced effector memory CD8 T cells did not prevent infection. Escape variants emerged rapidly in the group 1 vaccinees, and ultimately, the numbers of ECs were similar in groups 1 and 2. High-frequency vaccine-induced CD8 T cells focused on a single conserved epitope and therefore did not prevent infection or increase the incidence of elite control in Mamu-B*08 macaques.

IMPORTANCE
Since elite control of chronic-phase viremia is a classic example of an effective immune response against HIV/SIV, elucidating the basis of this phenomenon may provide useful insights into how to elicit such responses by vaccination. We have previously established that vaccine-induced CD8 T-cell responses against three immunodominant epitopes can increase the incidence of elite control in SIV-infected rhesus macaques—a model of HLA-B*27-mediated elite control. Here, we investigated whether a monotypic vaccine-induced Nef RL10-specific CD8 T-cell response targeting the conserved “late-escaping” Nef RL10 epitope can increase the incidence of elite control in Mamu-B*08 monkeys. Surprisingly, vaccine-induced Nef RL10-specific CD8 T cells selected for variants within days after infection and, ultimately, did not facilitate the development of elite control. Elite control is, therefore, likely to involve CD8 T-cell responses against more than one epitope. Together, these results underscore the complexity and multidimensional nature of virologic control of lentivirus infection.

Elite controllers (ECs) are a small subset of untreated human immunodeficiency virus type 1 (HIV-1)-infected patients who spontaneously control viral replication (1). Since they manifest durable control of HIV-1 infection in the absence of antiretroviral therapy (ART), considerable effort has been devoted to elucidating the basis for their successful outcome. Despite great heterogeneity within the group, several major histocompatibility complex class I (MHC-I) alleles, including HLA-B*57, HLA-B*27, and HLA-B*5801, remain the major determinants of elite control (1, 2). These associations, together with extensive characterization of HIV-1-specific cellular immune responses in ECs and normal progressors (3–8), implicate immunosurveillance by CD8 T cells as a key mediator of elite control. A better understanding of these efficacious CD8 T-cell responses could therefore provide useful clues for the development of HIV-1 vaccines.

Expression of the MHC-I alleles Mamu-B*08 and Mamu-B*17 also predisposes simian immunodeficiency virus (SIV)-infected Indian rhesus macaques to control viral replication (9, 10). In the case of Mamu-B*08, approximately 50% of monkeys expressing the allele become ECs, defined here as having a set point viral load (viral load) of <10^4 viral RNA (vRNA) copies/ml of plasma. It should be noted, however, that the penetrance of this effect can vary across
experiments and may depend on the route of challenge (9, 11–13). In comparison, SIVmac239-infected monkeys lacking protective MHC-I alleles often experience set point viral loads that exceed 10⁶ vRNA copies/ml (14). Consistent with a vital role of CD8⁺ T cells in establishing this phenotype, control of viral replication is impaired in Mamu-B*08⁰ monkeys infected with a SIVmac239 variant harboring escape mutations in multiple epitopes restricted by the allele (13). Furthermore, early CD8⁺ T-lymphocyte escape is a hallmark of Mamu-B*08⁰ animals that fail to contain SIVmac239 replication (11). Interestingly, Mamu-B*08⁰-restricted epitopes conform to a peptide binding motif that greatly resembles that of HLA-B*27, characterized by a requirement for an Arg at position 2 and a predilection for hydrophobic or basic amino acids at the carboxyl termini of their epitopes (15). Given these similarities, SIV-infected Mamu-B*08⁰ macaques may provide a useful model to study HLA-B*27-mediated elite control in humans.

The dominance of HLA-B*27-restricted CD8⁺ T-cell responses observed during primary HIV-1 infection is also recapitulated in SIV-infected Mamu-B*08⁰ macaques. However, instead of focusing on Gag (16), three epitopes (Vif RL9 [amino acids {aa} 123 to 131], Vif RL8 [aa 172 to 179], and Nef RL10 [aa 137 to 146]) account for more than half of the antiviral CD8⁺ T-cell response in Mamu-B*08⁰ ECs (17). Importantly, we have recently shown that these three immunodominant CD8⁺ T-cell responses are responsible for elite control in this animal model. That is, after a high-dose intrarectal (i.r.) challenge with SIVmac239, Mamu-B*08⁰ macaques vaccinated with Vif RL9, Vif RL8, and Nef RL10 manifested better control of viral replication than MHC-I-matched animals immunized with SIV inserts lacking any Mamu-B*08⁰-restricted determinants (12). Interestingly, an inverse association between peak VLs and the magnitude of CD8⁺ T cells directed against Nef RL10 was the only correlate of protection identified, implying that these Nef-specific responses were decisive for the challenge outcome.

Consistent with these results, CD8⁺ T cells directed against Nef RL10, but not Vif RL9 or Vif RL8, have also been linked to lower set point viremia in primary SIVmac239 infection (D. Douek, personal communication). Moreover, the Nef RL10-specific CD8⁺ T cells mobilized in ECs contained significantly more public T-cell receptor clonotypes than the responses detected in normal progressors (D. Douek, personal communication). Although conventional immunological measurements have been unable to explain these discordant associations (18), unique features of Nef RL10 suggest that it is indeed a useful target for CD8⁺ T-cell responses in Mamu-B*08⁰ animals. Namely, this epitope lies within the central region of Nef, which is relatively conserved and contains many CD8⁺ T-cell targets that contribute to immune control of HIV-1 replication (19). In fact, Nef RL10 is homologous to the HLA-B*27:05-restricted Nef RL10 (aa 105 to 114) epitope in HIV-1 (19). Furthermore, a recent analysis of viral sequence evolution in SIV-infected Mamu-B*08⁰ macaques revealed that Nef RL10 escape mutations occur later in the infection than those detected in Vif RL9 and Vif RL8 (11). Additionally, the mode by which SIV escapes from Nef RL10-specific CD8⁺ T cells is unusual compared to the mutational pathways described for other SIV epitopes, since it requires an Ala-to-Pro substitution immediately upstream of the Nef RL10 sequence (A₁₃₅P) (20). This change at position –1 likely interferes with NH₂-terminal trimming of the optimal epitope by the endoplasmic reticulum aminopeptidase I, as shown previously for the HLA-B*57:03-restricted Gag IW9 (aa 147 to 155) epitope (21). This atypical and delayed escape pattern suggests that it is difficult for the virus to avoid immunosurveillance by Nef RL10-specific CD8⁺ T cells. These observations, together with the correlate analysis from our previous experiment, prompted us to hypothesize that a vigorous Nef RL10-directed CD8⁺ T-cell response would be sufficient to establish elite control or even to block acquisition of SIV infection in Mamu-B*08⁰ animals.

To test this hypothesis, we engendered high-frequency CD8⁺ T-cell responses against Nef RL10 by vaccinating Mamu-B*08⁰ macaques several times with a nef minigene. Our controls consisted of a group of Mamu-B*08⁰ animals that were immunized with the same nef insert harboring amino acid substitutions around and within Nef RL10 designed to inactivate the epitope. Although macaques in both groups developed Nef-specific cellular immune responses, only those vaccinated with the intact epitope mounted CD8⁺ T cells against Nef RL10. These narrowly targeted CD8⁺ T-cell responses reached high frequencies, displayed markers of effector memory T cells (TEM₁), and were present at mucosal surfaces and secondary lymphoid organs (SLO) at the time of challenge. Here, we report the efficacy of these vaccine-induced Nef RL10-specific CD8⁺ T-cell responses after repeated i.r. challenges with SIVmac239.

**MATERIALS AND METHODS**

**Research animals.** Eighteen Mamu-B*08⁰ Indian rhesus macaques (Macaca mulatta) were used in this study, all of which were housed at the Wisconsin National Primate Research Center (WNPRC). They were cared for in accordance with the guidelines of the Weatherall Report under a protocol approved by the University of Wisconsin Graduate School Animal Care and Use Committee. Vaccinations, biopsies, and SIV challenges were performed under anesthesia, and all efforts were made to minimize suffering. Additional animal information, such as MHC-I genotype, age, and sex, is shown in Table 1.

**Vaccinations.** The macaques in groups 1 and 2 were vaccinated with two minigenes that encoded aa 45 to 210 of SIVmac239 Nef. The minigene delivered to group 1 corresponded to the wild-type (WT) SIVmac239 nef sequence, while the one given to group 2 contained several amino acid substitutions designed to inactivate the Nef RL10 epitope (Fig. 1A). These nef minigenes were inserted into three vector platforms: recombinant DNA (rDNA), yellow fever vaccine virus 17D (rYF17D), and adenovirus type 5 (rAd5). The rDNA constructs consisted of two pCMVkan plasmids (22), each carrying either the WT nef or the mutated nef minigene men-
toned above. Expression of these gene fragments was under the control of the human cytomegalovirus (CMV) promoter and the bovine growth hormone polyadenylation signal. The rDNA constructs were codelivered with the AG157 plasmid (23), which encodes the two subunits of rhesus interleukin 12 (IL-12) expressed from two separate transcription units. We refer to this plasmid as pIL-12 below. The animals were vaccinated intramuscularly with a mixture of 1.0 mg of rDNA plasmid containing the WT nef minigene and its mutated counterpart and 0.1 mg of plI-12 using the TriGrid in vivo electroporation system (Ichor Medical Systems, Inc., San Diego, CA). We primed the animals in groups 1 and 2 three times at 4-week intervals with electroporated (EP) rDNA plus plI-12.

Six weeks after the 3rd EP rDNA plus plI-12 vaccination, we boosted immune responses with the subcutaneous administration of 2.0 × 10^5 PFU of rYF17D vectors carrying the above-mentioned nef minigenes. The codon usage of these SIV sequences matched that of the YF17D virus. These live attenuated viruses were generated as described previously (24). The final rAd5 boost occurred 4 weeks after the rYF17D vaccination. The WT and mutated nef inserts were delivered by two rAd5 vectors that were made by ViraQuest, Inc., according to the RapAd method (25). Each rAd5 vector was administered intramuscularly at a dose of 10^11 viral particles in a final volume of 0.4 ml of PBS. Of note, both the rDNA and rAd5 vectors expressed nef minigenes that were codon optimized for high expression in mammalian cells.

**SIVmac239 challenges.** Eight weeks following the rAd5 boost, we began challenging all the animals with repeated intrarectal inoculations of 200 50% tissue culture infective doses (TCID_{50}) of SIVmac239. This corresponded to 4.8 × 10^5 vRNA copies. The animals were exposed to SIV on a weekly basis, and their plasma VLs were assessed 7 days later. If a macaque had a positive VL, it was no longer challenged. The number of challenges required to infect each monkey in this study is shown in Table 1.

**Sample processing.** We isolated PBMC from EDTA-treated blood by using Ficoll-Paque Plus (GE Health Sciences) density centrifugation. Red blood cells were lysed by treating PBMC with ACK buffer (H_2O containing 8.3 g/liter NH_4Cl, 1.0 g/liter KHCO_3, and 0.42 g/liter Na_3EDTA) for 5 min. The cells were subsequently washed in R10 medium (RPML 1640 medium supplemented with Glutamax [Life Technologies], 10% fetal bovine serum [FBS], and 1% antibiotic/antimycotic) and then resuspended at various concentrations depending on the application. Bronchoalveolar lavage (BAL) fluid was collected by the WNPRC staff by flushing saline solution into the bronchus and aspirating until fluid was no longer recovered. These cell suspensions were strained through a 100-μm cell strainer (BD Falcon), resuspended in R10, and then counted before flow cytometry analysis. Lymph node (LN) and rectal biopsy specimens were obtained as described previously (16). To process the LN biopsy specimens, we placed the tissue specimen in 100-μm cell strainers and gently pushed it against the nylon mesh using a 3-ml syringe plunger until the tissue was disrupted. We counted the cells in the ensuing cell suspension and then used it in immunological assays. Rectal biopsy specimens were washed once in R10 and then resuspended in collagenase medium (R10 with 0.5 mg/ml of type II collagenase from Clostridium histolyticum [Sigma-Aldrich]). After rocking the cells at 80 rpm for 30 min at 37°C on a tabletop shaker, we collected the supernatant and washed it twice with R10 medium. We repeated this digestion cycle two additional times. We then pooled the cells collected in each digestion cycle, layered them on top of a 40 to 90% Percoll gradient, and then centrifuged them at 450 × g for 30 min. Purified gut lymphocytes were collected from the interface between the 40% and 90% Percoll layers. We then washed the cells once with R10 medium, and then finally used them in immunological assays. Of note, all the tissues described above were harvested at the WNPRC and subsequently refrigerated at 4°C until they were shipped overnight to the University of Miami in a temperature-controlled package. Blood draws intended for viral load measurements were an exception. In those cases, the blood was processed shortly after venipuncture, and plasma aliquots were immediately frozen at −80°C.

**Memory phenotyping of MHC-I tetramer+ CD8+ T cells.** We used MHC-I-tetramers produced at the NIH Tetramer Core Facility conjugated to either allophycocyanin (APC) or phycoerythrin (PE) to label PBMC, BAL fluid, and cells isolated from LN or rectal biopsy specimens. Up to 8.0 × 10^6 cells were incubated in the presence of the appropriate fluorescein-chrome-labeled tetramer at 37°C for 1 h and then stained with monoclonal antibodies (MAbs) to the surface molecules CD3 (peridinin chlorophyll protein [PerCP] Cy5.5; clone SP34-2; BD Biosciences), CD8 (brilliant violet 421 [BV421]; clone RPA-T8; Biolegend, Inc.), CD28 (PE Cy7; clone CD28.2; Biolegend, Inc.), and CCR7 (fluorescein isothiocyanate [FITC]; clone 150503; BD Biosciences). To create a “dump channel,” we included LIVE/DEAD Fixable Aqua Dead Cell Stain (Life Technologies) and BV510-conjugated MAbs to CD14 (clone M5E2), CD16 (clone 3G8), and CD20 (clone 2H7) (all from Biolegend, Inc.) to the surface-staining mixture. After a 25-min incubation at room temperature, we treated the cells with BD FACS (fluorescence-activated cell sorter) lysing solution (BD Biosciences) for 10 min and subsequently washed them with wash buffer (Dulbecco’s phosphate-buffered saline [PBS] with 0.1% bovine serum albumin [BSA] and 0.45 g/liter NaCl). We permeabilized the cells by resuspending them in “Perm buffer” (1 × BD FACS lysing solution 2 [Becton Dickinson] and 0.05% Tween 20 [Sigma-Aldrich]) for 10 min. We then washed the cells once and stained them with a granzyve B (Gzm B)-specific MAb (PE; clone GB12; Life Technologies). After a 30-min incubation in the dark at room temperature, we washed the cells and stored them at 4°C until acquisition. Samples were acquired using FACS Diva version 6 on a Special Order Research Product BD LSR II apparatus equipped with a 50-mW 405-nm violet laser, a 100-mW 488-nm blue laser, and a 30-mW 635-nm red laser.

We used FlowJo 9.6 (TreeStar, Inc.) to analyze data. First, we gated on diagonally clustered singlets by plotting forward scatter height (FSC-H) versus FSC area (FSC-A) and then side scatter height (SSC-H) versus SSC area (SSC-A). Next, we created a time gate that included only those events that were recorded within the 5th and 90th percentiles and then gated on dump channel-negative, CD3+ cells. At this stage, we delineated the lymphocyte population based on its FSC-A and SSC-A properties and subse-

---

**Table 1: Animal characteristics**

<table>
<thead>
<tr>
<th>Exptl group</th>
<th>Animal ID</th>
<th>MHC-I allele(s)</th>
<th>Age (yr)*</th>
<th>Gender</th>
<th>Infecting challenge no.*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>r01068</td>
<td>Mamu-B*08</td>
<td>11.2</td>
<td>Male</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>r04001</td>
<td>Mamu-B*08</td>
<td>9</td>
<td>Female</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>r06008</td>
<td>Mamu-B*08</td>
<td>7</td>
<td>Female</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r08017</td>
<td>Mamu-A<em>02, -B</em>08, -B*17</td>
<td>4.4</td>
<td>Male</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r08018</td>
<td>Mamu-B*08</td>
<td>4.4</td>
<td>Female</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>r08020</td>
<td>Mamu-B*08</td>
<td>4.4</td>
<td>Female</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>r09029</td>
<td>Mamu-B*08</td>
<td>3.6</td>
<td>Male</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r09089</td>
<td>Mamu-B*08</td>
<td>3.2</td>
<td>Male</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>rh2099</td>
<td>Mamu-B*08</td>
<td>23.5</td>
<td>Male</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>r97076</td>
<td>Mamu-B*08</td>
<td>15.3</td>
<td>Female</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>r08016</td>
<td>Mamu-B*08</td>
<td>4.5</td>
<td>Male</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>r08032</td>
<td>Mamu-B*08</td>
<td>4.5</td>
<td>Female</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r08054</td>
<td>Mamu-B*08</td>
<td>4</td>
<td>Male</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r09014</td>
<td>Mamu-B*08</td>
<td>3.8</td>
<td>Male</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>r09037</td>
<td>Mamu-B*08</td>
<td>3.6</td>
<td>Female</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>r09068</td>
<td>Mamu-B*08</td>
<td>3.4</td>
<td>Female</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>r04087</td>
<td>Mamu-B*08</td>
<td>8.3</td>
<td>Female</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>r09092</td>
<td>Mamu-A<em>02, -B</em>08</td>
<td>3</td>
<td>Male</td>
<td>6</td>
</tr>
</tbody>
</table>

*Animal age at beginning of study.

*Interrectal challenge at which the animal became productively infected with SIVmac239.
quently gated on CD8\(^+\) cells. After outlining tetramer\(^+\) cells, we conducted our memory phenotyping analysis within this gate. Cells stained with fluorochrome-labeled MAbs of the same isotypes as the anti-granzyme B, anti-CD28, and anti-CCR7 MAbs guided the identification of the memory subsets within the tetramer\(^+\) population. Based on this gating strategy, all tetramer frequencies mentioned in this paper correspond to percentages of live CD3\(^+\) CD8\(^+\) tetramer\(^+\) lymphocytes.

ICS assay. For T-cell stimulation, we used two pools of 15-mers overlapping by 11 aa. The "Nef ORF" pool contained 64 15-mers spanning the entire SIV Nef open reading frame (ORF), while the "Nef ORF\_RL10" pool lacked the four 15-mers that contained the Nef RL10 epitope. The final assay concentration of each 15-mer was 1.0 \(\mu\)M. These peptide mixtures were used in the presence of costimulatory MAbs directed against CD28 (clone L293; BD Biosciences) and CD49d (clone 9F10; BD Pharmingen). We used leukocyte activation cocktail (LAC) (BD Pharmingen) as the positive control and tissue culture medium devoid of stimulatory peptides as the negative control. To measure CD107a externalization, we included a MAb specific for CD107a (PE; clone H4A3; Biolegend, Inc.) to the stimulation cocktail. We set up the intracellular cytokine staining (ICS) assay in 12- by 75-mm polypropylene tubes (Corning, Inc.) containing 1.5 \(\times\) 10\(^6\) PBMC in a final volume of 1.0 ml of R10. After adding the appropriate stimulation cocktails to each tube, the cells were placed in a 5.0% CO\(_2\) incubator at 37°C for 9 h and then refrigerated to 4°C until staining with fluorochrome-labeled MAbs. To inhibit protein transport, we added brefeldin A (Biolegend, Inc.) and GolgiStop (BD Biosciences) to all tubes 1 h into the incubation period at concentrations of 5.0 \(\mu\)g/ml and 0.7 \(\mu\)g/ml, respectively.

We employed the same steps outlined above to stain molecules on the surfaces of cells and subsequently permeabilize them for the ICS step. The surface-staining master mixture included the following MAbs: CD3 (PerCP Cy5.5; clone SP34-2; BD Biosciences), CD4 (Alexa Fluor 700; clone L200; BD Biosciences), and CD8 (FITC; clone RPA-T8; Biolegend, Inc.). The dump channel reagents were the same as described above. For the ICS step, we stained the cells with MAbs to gamma interferon (IFN-\(\gamma\)) (BV421; clone 4S.B3; Biolegend, Inc.), tumor necrosis factor alpha (TNF-\(\alpha\)) (APC; clone Mab11; BD Biosciences), and IL-2 (PE Cy7; clone

---

**FIG 1** Experimental layout. (A) Amino acid alignment of the WT and mutated Nef immunogens delivered to animals in groups 1 and 2, respectively. Both constructs spanned aa 45 to 210 of SIVmac239 Nef. The box shows the position of Nef RL10 in the WT insert and the amino acid substitutions used to disrupt this epitope in the mutated immunogen. The asterisks below the sequence alignment indicate identical amino acid residues. (B) The Mamu-B\(^*\)08\(^*\) macaques in group 1 (n = 8) and group 2 (n = 8) were primed three times with EP rDNA plus pIL-12, followed by the administration of rYF17D and then a final boost with rAd5. The intervals between vaccinations are shown. The Mamu-B\(^*\)08\(^*\) monkeys in group 3 (n = 2) did not receive any vaccine regimen and served as additional controls for the experiment. Eight weeks after the rAd5 boost, we began challenging all the animals with 200 TCID\(_{50}\) of SIVmac239 delivered via the i.r. route.
MQI-17H12; Biolegend, Inc.). After a 1-h incubation in the dark at room temperature, we washed the cells and stored them at 4°C until acquisition. Samples were acquired in the same flow cytometer mentioned above and analyzed with FlowJo 9.6 (Treestar, Inc.).

After gating on the lymphocyte population according the strategy described above, we analyzed subsets based on their expression of either CD4 or CD8, but not both markers. To conduct functional analyses within these two compartments, we made gates for each function (IFN-γ, TNF-α, IL-2, and CD107α) and then employed the Boolean gate platform to generate a full array of possible combinations, equating to 16 response patterns when testing four functions (24 = 16). LAC-stimulated cells stained with fluorochrome-labeled mAbs of the same isotypes as the anti-IFN-γ, anti-TNF-α, anti-IL-2, and anti-CD107α mAbs guided the identification of populations that were positive for these effector markers. We used two criteria to determine the positivity of responses. First, the frequency of events in each Boolean gate had to be at least 2-fold higher than their corresponding values in negative-control tests (background). Second, the Boolean gates for each response had to contain ≥10 events. The percentages of responding CD4+ or CD8+ T cells (see Fig. 3; see Fig. S1 in the supplemental material) were calculated by adding the frequencies of positive responses producing any combination of the four immunological functions described above. Background subtraction and calculation of the frequencies of responding cells were performed with Microsoft Excel.

**SIV and rYF17D viral load measurements.** SIV VLs were measured from EDTA-anticoagulated plasma. VL quantification was performed according to a previously published protocol (26). The limit of reliable quantification as performed on an input volume of 0.5 ml of plasma was 30 vRNA copies/ml. To quantify rYF17D replication, we isolated RNA from 250 μl of EDTA-anticoagulated plasma using the MasterPure RNA purification kit (Epicentre) according to the manufacturer’s instructions. Viral RNA was reverse transcribed and amplified using the TaqMan Fast Virus 1-Step master mix (Applied Biosystems) in an Applied Biosystems 7500 Fast instrument. Each reaction mixture contained 7.5 μl of 4× TaqMan Fast Virus 1-Step master mix, 400 nM forward primer, 900 nM reverse primer, 250 nM probe (5′-FAM-6-carboxyfluorescein[ZEN/3′ IBQF (Iowa Black FQ quencher)], and 20 μl of RNA sample in a final volume of 30 μl. The sequences of the primers and probe have been described previously (27). The reverse transcription was performed at 30°C for 5 min. The quantitative-PCR (qPCR) conditions were 95°C for 20 s, followed by 40 amplification cycles of 95°C for 15 s and 60°C for 1 min. Samples were run in triplicate. The copy numbers of YF17D viral RNA were calculated by absolute quantitation using a standard curve for each run. The standard curve was generated by 10-fold dilutions of an in vitro transcript made with a Megascript ultra-high-yield kit (Invitrogen) and purified using a Megaclear kit (Ambion) according to the manufacturer’s instructions. The plasmid pCRII-TOPO vector (Invitrogen) containing a PCR amplicon with a YF17D sequence identical to nucleotides 9833 to 10333 of GenBank accession number U17066.1 served as the template for transcription. The limit of detection under standard assay conditions was approximately 14 vRNA copies/ml, and the accurate quantification range was between 140 and 1.4 × 105 vRNA copies/ml of plasma.

**Amplicon-based 454 sequencing of Nef** RL10. One to 3 ml of plasma was thawed on ice and centrifuged at 20,017 × g for 1.5 h at 4°C, after which the pellet was resuspended in 140 μl of the supernatant. The QIAamp viral RNA minikit (Qiagen) was used to isolate viral RNA according to the manufacturer’s protocol. The viral RNA was eluted in 60 μl of AVE buffer, aliquoted, and stored at −80°C for future reverse transcription (RT)-PCR. An amplicon-based 454 sequencing approach was used to analyze the Nef RL10 epitope, as previously described (11). In brief, primers were synthesized with Roche 454 amplicon (Lib-A) adaptor sequences, multiplex identifier tags (MID) 1 to 18, and sequence-specific regions (Nef; forward, 5′-ACTGGAAGGATTATTAC-3′, and reverse, 5′-GAGTTCTCTCCTGTACGCC-3′), which allowed multiplexing of up to 16 animals per amplicon combination per sequencing run. A single-step RT-PCR was carried out for each of the unique amplicon-animal-MID sequence combinations using a SuperScript III one-step RT-PCR system with platinum Taq high fidelity (Invitrogen). Each 25-μl reaction mixture contained 12.5 μl of 2X reaction mixture; a further 0.3 mM MgSO4; 1.0 μl of enzyme mixture; 0.2 μM (each) the sequence specific, adaptor/MID-tagged forward and reverse primers; and up to 10 μl of template RNA. Cycling parameters for the RT-PCR were as follows: 54°C for 30 min and 94°C for 2 min, followed by 40 cycles of 94°C for 15 s, 54°C for 30 s, and 68°C for 30 s. The last two steps were 68°C for 5 min and then holding at 10°C. Amplicons were visualized on a 1.0% agarose gel and purified using the Purelink quick gel extraction kit (Invitrogen). RT-PCR products were quantified using a Promega quantiflor-ST fluorometer (Promega) and analyzed for quality using an Agilent 2100 bioanalyzer with high-sensitivity DNA chips. For each sequencing run, up to 16 animal/amplicon samples were pooled in equimolar ratios, and 2.0 × 107 molecules of pooled sample were added to 107 DNA capture beads for a final ratio of 2 DNA molecules per bead. Emulsion PCR, enrichment, breaking, and DNA sequencing were all performed according to the GS Junior FLX titanium series manuals for Lib-A (Roche). Sequencing and run processing were performed on a GS Junior 454 sequencing instrument (Roche). We used the ReadClean 454 (RC454) and V-Phaser algorithms as previously described to call variants from the 454 data sets (28). In brief, RC454 was used to align reads to SIVmac239. They were subsequently corrected for sequencing-related artifacts, such as indels resulting from overcalls and undercalls in homopolymeric regions and carry forward and incomplete extension (CAFIE) errors. Furthermore, RC454 optimizes read alignments using coding-frame information. The V-Phaser algorithm was then used to distinguish an observed variant as a true variant from an amplification or sequencing artifact (29). All raw read files generated as part of this study are available at the NCBI sequence read archive under experiment accession number SR427183.

**Statistics.** We defined each animal’s peak VL as the highest VL measurement obtained during the first 4 weeks after infection. The set point viremia was determined as the geometric mean of VLs measured between week 10 postinfection (p.i.) and the last time point available for each animal. We compared VLs among groups by using the Mann-Whitney test. To determine if vaccinees in groups 1 and 2 differed in the rate at which they acquired SIV infection, we used the log rank test. For the correlation analysis, we compared the magnitudes of vaccine-induced CD8+ T-cell responses and the percentages of WT epitope reads by using the Spearman rank correlation test.

**RESULTS**

Here, we explored the hypothesis that a monotypic CD8+ T-cell response targeting Nef RL10 might be sufficient to control replication of the pathogenic SIVmac239 clone. To do this, we vaccinated 16 *Mamu-B*08+ macaques with two different minigenes encoding the central region of Nef (aa 45 to 210) (Fig. 1A). These inserts were identical, except that one of them harbored several mutations (including the A→P substitution) designed to inactivate the Nef RL10 epitope (Fig. 1A). We divided the animals into two groups based on which minigene they received; group 1 (n = 8) was vaccinated with the WT nef sequence, whereas group 2 (n = 8) received the mutated construct (Fig. 1B). Thus, animals in both groups would develop Nef-specific T-cell responses, but only those in group 1 would mount CD8+ T-cell responses against Nef RL10.

In our previous *Mamu-B*08 efficacy trial, we vaccinated animals with an rYF17D prime followed by an rAd5 boost encoding Vif R19, Vif R18, and Nef RL10 (12). Although this regimen elicited sizeable SIV-specific responses shortly after the rAd5 boost, less than 0.3% of vaccine-induced CD8+ T cells targeted these *Mamu-B*08-restricted epitopes on the day of challenge (DOC) (Fig. 2A). To improve immunogenicity in the present experiment,
we primed the macaques three times with EP rDNA plus pIL-12 before delivering the rYF17D and rAd5 vectors (Fig. 1B). Consistent with the efficiency of electroporated rDNA to prime cellular immunity (30, 31), the new EP rDNA plus pIL-12/rYF17D/rAd5 regimen was significantly more immunogenic than the previously reported rYF17D/rAd5 protocol. Indeed, we could already detect Nef RL10-specific CD8+ T cells by fluorochrome-labeled MHC-I tetramer staining in PBMC from the group 1 vaccinees as early as 2 weeks after the 3rd EP rDNA plus pIL-12 immunization (data not shown). The rYF17D boost further expanded these responses in nearly all the animals, with one vaccinee (r04001) having 7.2% of its CD8+ T cells targeting Nef RL10 at week 2 postvaccination.

FIG 2 Kinetics of vaccine-induced, Nef RL10-specific CD8+ T-cell responses in the group 1 animals. We employed fluorochrome-labeled MHC-I tetramers to monitor the expansion of Nef RL10-specific CD8+ T cells in the group 1 vaccinees at several time points after the rYF17D vaccination. (A) Comparison of the total magnitudes of vaccine-induced CD8+ T-cell responses detected in PBMC on the DOC between animals in group 1 and the rYF17D/rAd5 vaccinees (n = 8) from our latest Mamu-B*08 trial (12). The group 1 frequencies correspond only to Nef RL10-specific CD8+ T cells, whereas those computed for the rYF17D/rAd5 vaccinees include responses to Vif RL9, Vif RL8, and Nef RL10. The lines represent medians, and each symbol denotes one monkey. (B to E) We also performed tetramer staining in several tissues obtained from the group 1 vaccinees, including PBMC (B) and BAL fluid (C), and on single-cell suspensions obtained from biopsy specimens from LN (D) and rectum (E). The gating strategy to determine the percentages of tetramer+ CD8+ T cells is described in Materials and Methods. The vertical dashed lines in panels B to E indicate the time of the rAd5 boost. The arrows below the x axes of the graphs correspond to the day of the first i.r. SIV challenge (DOC).

Narrowly Focused CD8+ T Cells Accelerate Virus Escape

December 2015 Volume 89 Number 21
jvi.asm.org
Journal of Virology

November 2015 Volume 89 Number 21
jvi.asm.org
Journal of Virology

10807
Remarkably, these responses underwent massive proliferation following the rAd5 boost, peaking at 46%, 14%, and 13% of all peripheral CD8+ T cells measured in r04001, r09029, and r08018, respectively (Fig. 2B). Despite considerable contraction in the ensuing weeks, the median frequency of vaccine-elicited Nef RL10-specific CD8+ T cells in PBMC among the group 1 animals was 1.1% on the DOC, with two macaques at 6% and 17% (Fig. 2A and B). This corresponded to a 3.8-fold increase compared to the combined magnitude of DOC responses targeting Vif RL9, Vif RL6, and Nef RL10 measured in the rYF17D/rAd5 vaccinees from our previous study (Fig. 2A) (12).

To determine if these vaccine-induced CD8+ T cells accessed mucosal surfaces and SLO, we also performed tetramer staining on single-cell suspensions obtained from BAL fluid and biopsy specimens of rectum and LN. We could easily detect tetramer+ CD8+ T cells at these anatomical sites shortly after the rAd5 boost, although at variable frequencies (Fig. 2C to E). While the lungs harbored the greatest percentages of Nef RL10-specific CD8+ T cells at all time points analyzed (Fig. 2E), these responses peaked at less than 3.0% CD8+ T cells present in the LN and gut in the majority of the animals (Fig. 2D and E). Of note, we did not sample the gut on the DOC to avoid compromising the rectal mucosa immediately before the i.r. SIV challenge. Similar to the pattern observed in PBMC, r04001 and r08018 had the highest frequencies of Nef RL10-specific CD8+ T cells in the lungs, LN, and gut (Fig. 2C to E). Importantly, we did not detect vaccine-induced CD8+ T-cell responses against Nef RL10 in any of the group 2 macaques (data not shown).

We also evaluated whether vaccinees in groups 1 and 2 mounted CD4+ and CD8+ T-cell responses to other epitopes in the WT and mutated Nef immunogens after the rAd5 boost (Fig. 3). To do this, we stimulated PBMC with two pools of Nef peptides (15-mers overlapping by 11 aa); the first spanned the entire Nef ORF, whereas the second pool included the same peptides, except for the four 15-mers that contained the Nef RL10 epitope (Nef ORFΔRL10). This approach revealed that vaccine-induced CD8+ T-cell responses were equivalent in groups 1 and 2 at the time of the rAd5 boost but trended higher in group 1 in the next 2 weeks (Fig. 3A). Surprisingly, the group 2 macaque rh2099 had extremely high frequencies of CD8+ T-cell responses on the day of the rAd5 boost; 60% of its CD8+ T cells recognized both the Nef ORF and Nef ORFΔRL10 pools (Fig. 3A and B). These extraordinary CD8+ T-cell responses likely stemmed from the high levels of rYF17D replication experienced by the animal shortly after vaccination with this live-attenuated vector (see Fig. S1A in the supplemental material). Indeed, rh2099's rYF17D viremia reached 3.4 × 10^5 vRNA copies/ml of plasma on day 6 post-rYF17D vaccination, the largest plasma concentration of rYF17D detected in >25 rYF17D-immunized animals examined in previous studies conducted by our laboratory (see Fig. S1A in the supplemental material) (27, 32, 33). Subsequent ICS assays demonstrated that these high-frequency CD8+ T-cell responses were directed against a single epitope within aa 170 to 179 (TFGWLWKLV) (see Fig. S1B in the supplemental material). Except for r06008 and r08017, vaccinees in group 1 did not recognize the Nef ORFΔRL10 pool, confirming that their CD8+ T-cell responses were focused on Nef RL10 (Fig. 3B). The reactivity observed in r06008 and r08017 was likely due to vaccine-induced CD8+ T cells targeting epitopes restricted by other MHC class I alleles. The latter animal, for example, was also positive for Mamu-B*17 and developed CD8+ T-cell responses directed against two epitopes restricted by this allele, Nef IW9 (aa 163 to 173) and Nef MW9 (aa 195 to 203) (see Fig. S1C in the supplemental material) (34). Furthermore, macaques in both groups developed similar levels of CD4+ T-cell responses following the rAd5 boost, with r04001 in group 1 and rh2099 in group 2 mounting the highest frequencies of Nef-specific CD4+ T cells (Fig. 3C).

Next, we assessed the memory phenotype of vaccine-induced CD8+ T cells on the DOC by co-staining PBMC with the Mamu-B*08/Nef RL10 tetramer and antibodies directed against CD28, CCR7, and granzyme B (Gzm B) (Fig. 4A). Despite some intra-group variability, the majority of tetramer+ T cells expressed markers of either fully differentiated effector memory (TEM2; median, 57%) or transitional memory (TEM1; median, 27%) T cells (Fig. 4B). Gzm B was also expressed by these antigen (Ag)-specific CD8+ T cells (median, 64%), indicating their cytotoxic potential (Fig. 4C). Of note, these tetramer+ T cells were phenotypically similar to those elicited in our previous trial (Fig. 4D and E), suggesting that the three EP rDNA plus pL1-12 priming immunizations delivered to the group 1 animals did not significantly alter the memory phenotype of their vaccine-induced CD8+ T cells compared to the responses engendered by the rYF17D/rAd5 regimen.

Given the high frequencies of vaccine-induced CD8+ T-cell responses in our vaccinees, we set out to determine whether these Nef-specific responses could either affect acquisition of SIV infection or facilitate the establishment of elite control. To do this, we began challenging all the monkeys intrarectally with 200 TCID50 of SIVmac239 at week 8 following the rAd5 boost (Fig. 1B). These challenges occurred on a weekly basis and were discontinued once an animal became infected. As additional controls, we also subjected two unvaccinated Mamu-B*08+ rhesus macaques to this challenge regimen (group 3) (Fig. 1B). Three vaccinees were noteworthy on the DOC because of their high-frequency T-cell responses. The group 1 animals r04001 and r08018 had 17% and 6% of their peripheral CD8+ T cells targeting both the Nef170TFGWLWKLVP179 peptide on the DOC (see Fig. 2A in the supplemental material). In spite of these high-magnitude vaccine-induced CD8+ T-cell responses, vaccinees in groups 1 and 2 acquired SIV infection at similar rates (Fig. 5). Strikingly, r04001 and rh2099 became infected after the first i.r. challenge, while r08018 became viremic after the 7th virus exposure (Table 1). These results suggest that vaccine-induced CD8+ T cells directed against a single epitope cannot prevent lentivirus infection following i.r. challenge. Unexpectedly, it took 13 i.r. challenges to infect r09068 in group 2 and the unvaccinated Mamu-B*08+ monkey r04087 (Table 1). While r09068 remained aviremic until 1 week after its 13th virus exposure, r04087 experienced a VL “blip” of 40 vRNA copies/ml of plasma on the day of the 5th SIV inoculation. Since we could not confirm infection on a plasma sample obtained 3 days later, we did not interrupt the challenge schedule. Shortly after the 7th exposure, we detected a low-frequency Nef-specific CD8+ T-cell response in r04087 and decided to halt the challenges in order to determine whether the animal had acquired SIV infection. Attempts to recover SIV by coculturing PBMC or LN cells with CEMx174 cells yielded no replication-competent virus (data not shown). Although we mapped r04087’s Nef-specific CD8+ T-cell response to aa 65 to 83—a region lacking any previously
identified epitopes—we could not detect T-cell responses to Gag, Env, or Vif in the animal. Once we resumed challenging r04087 22 weeks after its last SIV exposure, it took 6 additional i.r. inoculations (13 in total) to productively infect the animal. Neither r04087 nor r09068 controlled viral replication after they became infected (Fig. 6B and C). It is unclear why these animals resisted more i.r. challenges than the rest of the macaques in this experiment.

Our next step was to determine if the robust Nef RL10-specific CD8\(^+\) T cells engendered in the group 1 vaccinees improved their ability to contain SIV infection compared to their group 2 counterparts and unvaccinated Mamu-B*08\(^+\) macaques. We found that infection outcomes varied considerably from animal to animal (Fig. 6A and B). For example, the two macaques mounting the highest frequencies of SIV-specific CD8\(^+\) T-cell responses on the DOC—r04001 in group 1 and rh2099 in group 2—did not control acute-phase viremia and subsequently had escalating VLs until week 20 p.i. (Fig. 6A and B). The group 2 macaques r97076, r09014, and r09068 also failed to establish durable control of SIV replication (Fig. 6B). Furthermore, while several group 1 vaccinees (r01068, r08017, r08020, and r09029) experienced episodes of controlled VLs (<1,000 vRNA copies/ml), SIV viremia eventually rebounded in those animals at later time points (Fig. 6A and B). Notably, however, three animals in group 1 (r06008, r08018, and

![Fig 3](https://example.com/figure.png)

**Fig 3** ICS analysis of vaccine-induced T-cell responses in groups 1 and 2 following the rAd5 boost. We carried out ICS assays in PBMC from the group 1 and group 2 macaques at weeks 0, 1, and 2 post-rAd5 boost. Our stimuli consisted of pools of peptides (15-mers overlapping by 11 aa) spanning the entire SIVmac239 Nef ORF (Nef ORF peptide pool) or lacking the four 15-mers containing the Nef RL10 sequence (Nef ORF\(\Delta\)RL10 peptide pool). The percentages of responding CD4\(^+\) or CD8\(^+\) T cells displayed in panels A to C were calculated by adding the frequencies of positive responses producing any combination of four immunological functions (IFN-\(\gamma\), TNF-\(\alpha\), IL-2, and CD107a). (A) Magnitudes of vaccine-induced CD8\(^+\) T-cell responses directed against the Nef ORF peptide pool in groups 1 and 2. (B) Magnitudes of vaccine-induced CD8\(^+\) T-cell responses directed against the Nef ORF\(\Delta\)RL10 peptide pool in groups 1 and 2. (C) Magnitudes of vaccine-induced CD4\(^+\) T-cell responses directed against the Nef ORF peptide pool in groups 1 and 2. The gating strategy to analyze these data is described in Materials and Methods. The lines represent medians, and each symbol denotes one monkey.
r09089) and four in group 2 (r08016, r08032, r08054, and r09037) became ECs, as defined by their chronic-phase VLs of less than 1,000 vRNA copies/ml (Fig. 6A and B). Additional follow-up was available for most of these ECs and revealed that they had undetectable VLs at weeks 69 to 73 p.i. (Fig. 6A and B). Together, these results demonstrated that vaccine-induced Nef RL10-specific CD8\(^+\) T cells did not affect the rate of elite control in the Mamu-B*08/macacaques in group 1 compared to their counterparts in group 2. This conclusion was corroborated by the similar peak and set point VLs measured in groups 1 and 2 (Fig. 6D and E). Al-

FIG 4 Memory phenotype of vaccine-induced, Nef RL10-specific CD8\(^+\) T cells in PBMC on the DOC. (A) Gating strategy used to delineate fully differentiated effector memory (TEM2), transitional memory (TEM1), or central memory (TCM) subsets within tetramer \(^{-}\) CD8\(^+\) T cells in peripheral blood. We also evaluated Gzm B (black lines) expression within tetramer \(^{-}\) CD8\(^+\) T cells, as shown in the histogram. The shaded area corresponds to tetramer \(^{-}\) CD8\(^+\) T cells stained with an isotype-matched control MAb. (B to E) We evaluated the memory phenotype (B and D) and Gzm B expression (C and E) of Nef RL10-specific CD8\(^+\) T cells measured in PBMC from the group 1 animals (B and C) or the rYF17D/rAd5 vaccinees (D and E) from our latest Mamu-B*08 trial (12). The group 1 and rYF17D/rAd5 tetramer staining assays were performed on freshly isolated and cryopreserved PBMC, respectively, using the same experimental conditions. Samples from only six of the latter vaccinees were available for this analysis. The lines represent medians, and each symbol denotes one monkey.

r09089) and four in group 2 (r08016, r08032, r08054, and r09037) became ECs, as defined by their chronic-phase VLs of less than 1,000 vRNA copies/ml (Fig. 6A and B). Additional follow-up was available for most of these ECs and revealed that they had undetectable VLs at weeks 69 to 73 p.i. (Fig. 6A and B). Together, these results demonstrated that vaccine-induced Nef RL10-specific CD8\(^+\) T cells did not affect the rate of elite control in the Mamu-B*08/macacaques in group 1 compared to their counterparts in group 2. This conclusion was corroborated by the similar peak and set point VLs measured in groups 1 and 2 (Fig. 6D and E). Although macaques in group 1 manifested a modicum of control at week 4 p.i. (Fig. 6F), this effect was transient, since groups 1 and 2 did not differ in their cumulative levels of viremia, as determined by a time-weighted area under the curve (AUC) analysis (Fig. 6G). The similarity of these virologic parameters was unexpected, considering recent data suggesting that Nef RL10 is a useful target for CD8\(^+\) T-cell responses in Mamu-B*08/macacaques (D. Douek, personal communication) (12, 17, 20). Nevertheless, compared to SIV infection of unvaccinated Mamu-B*08/macacaques (two animals in group 3 and four historical controls), vaccinees in group 1 still achieved significant reductions in plasma viremia (Fig. 6D to F). This analysis also revealed trends toward lower week 4 and set point VLs in the group 2 animals (Fig. 6E and F). Thus, vaccine-induced Nef RL10-specific CD8\(^+\) T cells decreased viral replica-
time point (Fig. 8A). Together, these results demonstrate that selective pressure imposed by vaccine-induced CD8+ T cells can precipitate sequence evolution in the AIDS virus within days of mucosal transmission, even if these responses are directed against a "late-escaping" epitope, such as Nef RL10 (Table 2).

Lastly, we set out to identify biological variables that dictated the patterns of immune escape observed in groups 1 and 2. We began by comparing sequencing results obtained at week 6 p.i. between the present study and our latest Mamu-B*08+ trial (12). Unfortunately, data from only four of the latter animals were available for this analysis, which limited our statistical power (Fig. 9A). In spite of this caveat, the percentage of WT epitope reads in the group 1 vaccinees trended lower than that measured in the four rYF17D/rAd5-immunized animals from our earlier study (Fig. 9A). Since viral replication is needed to spawn epitope mutants, we examined whether the group 1 macaques selected for faster sequence variation because they experienced greater levels of acute-phase viremia than their rYF17D/rAd5 counterparts. In contrast to this prediction, a reevaluation of plasma virus concentrations on freshly thawed samples from animals in both groups using the same quantitative-PCR conditions showed that they had equivalent peak VLs (Fig. 9B). Our next step was to test if the total size of vaccine-induced Nef RL10-specific CD8+ T-cell responses dictated the escape rates observed after infection. Unfortunately, we could not perform this analysis on the rYF17D/rAd5-immunized macaques because of the limited size of the sequencing data set. Tellingly, however, we observed an inverse trend between the magnitude of Nef RL10-directed CD8+ T cells measured in the group 1 animals on the DOC and the frequency of WT epitope reads at week 2.4 (Fig. 9C). To further explore this issue, we examined the levels of tetramer+ CD8+ T cells present in PBMC, LN, and rectum samples from animals in groups 1 and 2 at week 2.4 p.i. As expected, Nef RL10-specific CD8+ T cells in group 1 greatly outnumbered those measured in the group 2 macaques, whereas the frequencies of primary CD8+ T-cell responses targeting Vif RL8 and Vif RL9 were similar in the two groups (Fig. 9D to F). Notably, for all three tissues assessed, the frequency of WT epitope reads was inversely associated with the number of Nef RL10-specific CD8+ T cells detected at this time point (Fig. 9G). Since r04001 was an outlier in these analyses, we repeated the above-mentioned comparisons in the absence of its data and found that all associations remained significant (PBMC, \( P = 0.01 \), \( r = -0.63 \); LN, \( P = 0.0009 \), \( r = -0.78 \); rectum, \( P = 0.02 \), \( r = -0.6 \)). Curiously, however, the magnitude of acute-phase Nef RL10-specific CD8+ T-cell responses did not predict the frequency of epitope mutants observed at week 6 p.i. (Fig. 9H). Collectively, these findings indicate that during acute SIV infection, the magnitude of contemporaneous CD8+ T-cell responses directed against Nef RL10 dictated the amount of sequence evolution within the epitope.

**DISCUSSION**

In HIV-1-infected HLA-B*27+ ECs, virologic control may be critically dependent on CD8+ T-cell responses targeting a single epitope, Gag KK10 (aa 263 to 272) (5, 16, 35). Given the similarities between HLA-B*27-mediated elite control and this phenomenon in SIV-infected Mamu-B*08+ rhesus macaques (15, 36), we investigated whether narrowly focused CD8+ T-cell responses against a single Nef epitope would also be sufficient to suppress SIV replication. We chose to investigate the protective efficacy of
A) Group 1 VLs

B) Group 2 VLs

C) Group 3

D) Peak VLs

E) Setpoint VLs

F) Wk 4 VLs

G) AUC VLs
immunization with the Mamu-B*08-restricted Nef RL10 epitope due to its delayed and unusual escape pattern (17) and sequence conservation (19) and recent immunological data linking Nef RL10-specific CD8$^+$ T cells with improved challenge outcome (12). In spite of these presumably desirable characteristics for a vaccine target, the high-frequency Nef RL10-directed CD8$^+$ T cells elicited in the group 1 animals failed to affect SIV acquisition and did not increase the incidence of EC status. Furthermore, these high-frequency T$_{EM}$ responses afforded only a transient reduction in plasma viremia compared to the Nef-specific cellular responses engendered in the group 2 macaques that targeted epitopes other than Nef RL10. The most striking finding of this study was the rapidity with which Nef RL10-specific CD8$^+$ T cells selected for escape variants after infection; indeed, viral mutants

FIG 6 Plasma virus concentrations after SIVmac239 infection. (A to C) Macaques in group 1 (A), group 2 (B), and group 3 (C) acquired SIV infection after various i.r. exposures (Table 1). The VLs were log transformed and correspond to the number of vRNA copies/ml of plasma. The dashed lines in all the graphs are for reference only and indicate a VL of $10^3$ vRNA copies/ml. The solid lines in panels A to C are also for reference only and denote a VL of $10^6$ vRNA copies/ml. (D to F) We compared the median peak (D), set point (E), and week 4 (F) VLs among animals in group 1 and group 2 and unvaccinated Mamu-B*08 controls using the Mann-Whitney test. The lines represent medians, and each symbol denotes one monkey. The average numbers of sequencing reads obtained from animals in groups 1 and 2 at this time point were 2,747 and 6,971, respectively.

FIG 7 Frequencies of WT and mutated Nef RL10 epitope reads at week 6 p.i. (A and B) We used an amplicon-based 454 pyrosequencing approach to characterize the viral quasispecies that constitute the Nef RL10 epitope in virus replicating in the group 1 (A) and group 2 (B) animals at week 6 p.i. All variants detected in >1% of sequenced reads are listed. Individual mutants that comprised <1% of sequenced reads were grouped in the same category (Variants <1%), and their combined frequencies are shown. The frequency of the predominant viral quasispecies in each animal is in boldface. Elite-controller macaques are marked with “EC” above their identifiers (IDs). (C) Comparison of the percentages of WT epitope reads detected in plasma from the group 1 and group 2 macaques at week 6 p.i. using the Mann-Whitney test. The lines represent medians, and each symbol denotes one monkey. The average numbers of sequencing reads obtained from animals in groups 1 and 2 at this time point were 2,747 and 6,971, respectively.
comprised almost 90% of the virus replicating in the group 1 vaccinee r04001 at week 2.4 p.i. and became widespread in half of the animals in this group by week 6 p.i. This rate was considerably higher than those reported in primary infection and in the rYF17D/rAd5 vaccinees from our latest Mamu-B*08 trial (12, 17).

These results are best interpreted in light of past reports of SIV sequence evolution in the face of strong selective pressure mediated by the host’s CD8\(^+\) T-cell response. For example, a similar outcome has been achieved in Tat-vaccinated Mamu-A*01/macacaques, where monotypic vaccine-induced CD8\(^+\)/T-cell responses against Tat SL8 (aa 28 to 35) were swiftly evaded by mutational escape shortly after challenge with SIVmac239 (37). However, an important distinction between this past study and the present one is the fact that even in unvaccinated monkeys, Tat SL8 mutants can largely replace WT virus within 4 weeks of infection without incurring any fitness cost to the virus (38, 39).

Although Nef RL10 exhibits a lower escape rate, with most viral variants beginning to appear at week 8 p.i. (11, 17), it is not clear if this epitope is functionally constrained. Notably, a 12-bp deletion corresponding to the amino acids 143-DMYL146 in SIVmacC8 Nef has been shown to decrease protein stability and function in vitro and likely contributes to the attenuated phenotype of this strain in vivo (40).

The overlap between this deletion and Nef RL10 indicates that the region is indeed functionally constrained. Longitudinal sequencing analyses, such as the one conducted here, also support this conclusion. For instance, during primary infection of Mamu-B*08/macacaques, the earliest Nef RL10 mutants to emerge tend to harbor amino acid changes at various positions within the epitope, but not in the A136 residue that immediately precedes the minimal optimal peptide (11, 12). Interestingly, once the putative A136P processing mutation becomes fixed in the viral population, which typically occurs later in the chronic phase, the internal sequence of the Nef RL10 epitope almost invariably reverts to WT (11, 12, 17). Indeed, that was the case with nearly all the monkeys.

FIG 8 Frequencies of WT and mutated Nef RL10 epitope reads at week 2.4 p.i. (A and B) Similar to the description in the legend to Fig. 7, we characterized the viral quasispecies that constitute the Nef RL10 epitope in virus replicating in the group 1 (A) and group 2 (B) animals at week 2.4 p.i. All variants detected in >1% of sequenced reads are listed. Individual mutants that comprised <1% of sequenced reads were grouped in the same category (Variants <1%), and their combined frequencies are shown. The frequency of the predominant viral quasispecies in each animal is in boldface. Elite-controller macaques are marked with “EC” above their IDs. (C) Comparison of the percentages of WT epitope reads detected in plasma from the group 1 and group 2 macaques at week 2.4 p.i. using the Mann-Whitney test. The lines represent medians, and each symbol denotes one monkey. The average numbers of sequencing reads obtained from animals in groups 1 and 2 at this time point were 3,194 and 2,333, respectively.
in the present study, although the intense selective pressure imposed by the anamnestic CD8⁺ T cells mounted by the group 1 vaccinees accelerated this process. We also recently inoculated Mamu-B*08-negative animals with a SIVmac239 variant encoding several Mamu-B*08-associated escape mutations, including A₁₃₆P (41). Of note, this “escaped” virus did not replicate as well as WT SIVmac239 in vivo, but it is not clear if this impaired replicative capacity was due to A₁₃₆P or the other changes introduced in its backbone. Notably, a characterization of the viral quasispecies circulating in those animals in the chronic phase revealed that the A₁₃₆P substitution did not revert to WT, indicating that it can stably maintain in vivo in the absence of CD8⁺ T-cell-mediated pressure (41). Based on these data, one might envision a scenario in which SIV initially tries to evade the host CD8⁺ T-cell response by mutating the internal residues of Nef RL10 epitope at position 8 of the Nef RL10 epitope in vivo. The impressive virologic control mediated by this animal. The infection outcomes for monkeys r08018 (group 1) and r08032 (group 2) provided further evidence of the poor prognostic value of Nef RL10 escape, since WT epitope reads were nearly absent from their viral quasispecies at week 6 p.i. and yet they ended up controlling chronic-phase viremia. On the other hand, the fact that Nef RL10 was intact in the virus replicating in the group 2 macaques rh2099, r97076, and r90914 at week 6 p.i. also did not predispose them to control viral replication. These discordant associations between the extents of sequence variation within Nef RL10 and disease progression are not surprising considering that multiple genetic, virologic, and immune factors have been shown to affect control of lentivirus infection (1, 42).

Of note, rapid escape driven by vaccine-induced CD8⁺ T cells has been linked to virologic control in SIV-infected Burmese rhesus macaques (43). In that study, Matano et al. vaccinated eight animals with an rDNA prime followed by a recombinant Sendai virus (rSeV) vector boost encoding Gag and subsequently challenged them with SIVmac239 intravenously. Notably, 5/8 vaccinees controlled viral replication to undetectable levels after week 5 p.i. Subsequent analyses of SIV gag sequences in all the immunized animals revealed that virologic control was linked to escape in a few Gag epitopes, which resulted in less fit viruses (43, 44). These results are in contrast to those reported here, where vaccine-elicted CD8⁺ T cells directed against Nef RL10 precipitated escape in this epitope without any overt effect on viral replication. The reasons for these discrepant outcomes are difficult to assess given the many biological variables that distinguish our experiment from...
A) % of WT epitope reads at wk 6 pi

B) Re-evaluation of peak VLs

C) Nef RL10-specific CD8+ T-cells on DOC versus % of WT epitope reads

D) Acute phase CD8+ T-cells in PBMC

E) Acute phase CD8+ T-cells in LN

F) Acute phase CD8+ T-cells in rectum

G) Acute phase Nef RL10-specific CD8+ T-cells versus % of WT epitope reads at wk 2.4 pi

H) Acute phase NefRL10-specific CD8+ T-cells versus % of WT epitope reads at wk 6 pi

FIG 9 Biological variables affecting the kinetics of CD8+ T-cell escape within Nef RL10. (A) Comparison of the frequencies of WT Nef RL10 sequence reads detected at week 6 p.i. between group 1 and the rYF17D/rAd5-immunized animals in our latest Mamu-B*08 trial (12). Data from only four rYF17D/rAd5 vaccinees were available for this comparison. (B) Reevaluation of peak viral loads in macaques in group 1 and the rYF17D/rAd5 vaccinees. To avoid interassay variability, we determined plasma virus concentrations on freshly thawed samples using the same quantitative-PCR conditions. We used the Mann-Whitney test to calculate P values for the analyses depicted in panels A and B. The lines represent medians. (C) Magnitudes of Nef RL10-specific CD8+ T cells in PBMC of the group 1 animals on the DOC compared to their corresponding frequencies of viral quasispecies encoding WT Nef RL10 (WT epitope reads) measured at week 2.4 p.i. (D to F) Magnitudes of CD8+ T cells specific for the Mamu-B*08-restricted Nef RL10, Vif RL8, and Vif RL9 epitopes present in PBMC (D), LN (E), and rectum (F) from animals in groups 1 and 2 at week 2.4 p.i. (G and H) Magnitudes of acute-phase Nef RL10-specific CD8+ T cells in PBMC, LN, and rectum from animals in groups 1 and 2 compared to their corresponding frequencies of WT epitope reads at week 2.4 (G) and 6 (H) p.i. We determined the correlation coefficients in panels C, G, and H by using the Spearman rank correlation test. Each symbol denotes one monkey. ND, not done.
that conducted by Matano and colleagues. However, the fact that the rDNA/rSeV vaccines targeted multiple Gag epitopes (44), some of them under structural constraints, suggests that the fitness cost for escaping from these Gag-directed CD8\(^+\) T-cell responses would be higher than that required to evade the Nef RL10-specific CD8\(^+\) T cells elicited in the present study.

Although the magnitude of Nef RL10-specific CD8\(^+\) T cells measured in the group 1 and group 2 animals at week 2.4 p.i. was correlated with their contemporaneous rates of immune escape, this association did not hold for the sequence variation detected at week 6 p.i. The fact that these acute-phase CD8\(^+\) T-cell responses lost their predictive power during the 4-week interval that separated the above-mentioned time points underscores the complexity of virus-host interactions during lentivirus infection. The high antigen loads that result from HIV/SIV infection, for instance, are well known to be detrimental to T-cell immunity (45). Along these lines, Fujita et al. have recently reported the expansion of dysfunctional CD8\(^+\) T cells expressing programmed death 1 (PD-1) and T-cell Ig- and mucin domain-containing molecule 3 (Tim-3) during acute SIV infection (46). Differential upregulation of these inhibitory receptors could therefore help explain the discordance between the postchallenge responses developed by r01068 and r04001 in group 1 and their respective rates of immune escape at week 6 p.i. Despite mounting equally abundant anamnestic Nef RL10-specific CD8\(^+\) T cells, the virus replicating in the former animal encoded an intact epitope whereas only escape mutants were detected in r04001. It was also unclear why viral variants had replaced WT sequences in the group 2 macaque r08032 at week 6 p.i., given its scant CD8\(^+\) T-cell response to Nef RL10 after infection. Nevertheless, it is important to bear in mind that interhost heterogeneity can exist in CD8\(^+\) T cells restricted by the same MHC-I molecule and specific for the same epitope, even among genetically identical mice (47). Indeed, continuous priming of naive CD8\(^+\) T cells that are phenotypically distinct from their Ag-specific memory counterparts can affect the outcome of chronic viral infections (48). T-cell receptor (TCR) clonotype usage has also been shown to govern patterns of viral sequence evolution and the ability of CD8\(^+\) T cells to recognize epitopes bearing common escape mutations (49, 50). Given these intricate biological variables, CD8\(^+\) T-cell frequency alone may no longer be able to dictate the kinetics of immune escape once productive HIV/SIV infection is established.

Recent studies have demonstrated that T\(_{EM}\) responses induced by persistent herpesviral vectors, such as rhesus cytomegalovirus (RhCMV), can afford superior virologic control in SIV-infected monkeys. Notably, Hansen et al. have reported that approximately 50% of RhCMV-vaccinated macaques manifest profound and early control of SIVmac239 replication, regardless of the challenge route, and subsequently clear the virus (51, 52). In the present study, we delivered a total of five immunizations as part of the EP rDNA plus pL-12/3rfYFD17/rAd5 modality, RhCMV vaccination results in T-cell repertoires of greater breadth than conventional vaccine platforms. The latter feature may be particularly important for the protective impressiveness conferred by this herpesviral vector, considering the apparent ease with which SIV evaded Nef RL10-directed CD8\(^+\) T-cell responses in the present experiment. A similar outcome has actually been reported in a vaccinated HLA-B*27\(^+\) person who subsequently acquired HIV-1 infection (56). Despite mounting CD8\(^+\) T-cell responses to Gag KK10, a structurally constrained epitope whose canonical escape mutation (R\(_{EM}\)K) imparts a severe fitness cost to the virus, this individual did not exhibit clinical signs of controlled infection. Alarmingly, Gag KK10 escape variants emerged at a higher rate than previously reported during primary infection (5, 56). Thus, monotypic CD8\(^+\) T-cell responses can accelerate the selection of viral mutants even if the targeted epitope lies within conserved, functionally constrained regions of HIV/SIV.

In conclusion, here, we show that high-frequency effector memory Nef RL10-specific CD8\(^+\) T-cell responses elicited by vaccination do not affect either the rate of SIV acquisition following repeated i.r. challenges or the incidence of elite control in Mamu-B*08\(^+\) macaques. Despite the conserved nature of Nef RL10 and its delayed escape pattern, the intense selective pressure exerted by these vaccine-induced CD8\(^+\) T cells accelerated the emergence of epitope variants after infection. Furthermore, we observed instances of mutational escape preceding virologic control or leading up to breakthrough viremia, suggesting that the protective efficacy of Nef RL10-specific CD8\(^+\) T cells can vary substantially among Mamu-B*08\(^+\) macaques. Our results also have implications for vaccine strategies aimed at eliciting cellular immunity against HIV-1, since they demonstrate that lentiviruses can exploit their genetic malleability to evade narrowly focused CD8\(^+\) T cells within days of infection, even if these responses are directed against a conserved epitope. This may be analogous to treating HIV-1-infected individuals with a single drug (leading to rapid escape) compared to several drugs that ultimately delay the emergence of escape mutations (57). Alternatively, considering that an rYF17D/rAd5 regimen encoding Vif RL8, Vif RL9, and Nef RL10 resulted in the establishment of elite control in 6/8 Mamu-B*08\(^+\) macaques following challenge with SIVmac239 in our previous experiment (12), it is possible that Nef-specific CD8\(^+\) T cells may not be as effective as those directed against Vif. Ongoing studies in our laboratory will hopefully address this hypothesis.

ACKNOWLEDGMENTS

This work was funded by Public Health Service grant R37AI052056 to D.I.W. and was supported in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E and from the National Institute of Allergy and Infectious Diseases through P01 AI074415 (T.M.A.). This work was also partially funded by the International AIDS Vaccine Initiative (IAVI) with the generous support of the U.S. Agency for International Development
The contents of the manuscript are our responsibility and do not necessarily reflect the views of USAID or the U.S. government.

We thank Teresa Maidana Giret for confirming the MHC-I genotype of the monkeys in this study; Iris Castro for administrative assistance; Michael Ricciardi, Rebeca Alvarez, Kim Weisgrau, Jessica Furlott, Randy Fast, Kelli Oswald, and Rebecca Shoemaker for technical support; Peng Li for assistance with statistical analyses; and Eric Peterson and Kristin Cronso for providing excellent care of the rhesus macaques used in the experiment. We also thank Louis Picker, Scott Hansen, and Andrew Sylvester for sharing their expertise on intracellular-cytokine-staining measurements.

REFERENCES


